Angela Meade

Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial

Tim Maughan, Richard Adams, Christopher G. Smith et al. · The Lancet · 2011 · 964 citations

Gastrointestinal Oncology, Medicine, Randomised Phase 3 +8

<i>KRAS</i> and <i>BRAF</i> Mutations in Advanced Colorectal Cancer Are Associated With Poor Prognosis but Do Not Preclude Benefit From Oxaliplatin or Irinotecan: Results From the MRC FOCUS Trial

Susan D. Richman, Philip Chambers, Faye Elliott et al. · Journal of Clinical Oncology · 2009 · 567 citations

Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial

Tim Maughan, Jonathan A. Ledermann, C. Topham et al. · The Lancet · 2007 · 564 citations

Mrc Focus, Surgical Oncology, Different Strategies +7

Predictive Biomarkers of Chemotherapy Efficacy in Colorectal Cancer: Results From the UK MRC FOCUS Trial

Michael Braun, Susan D. Richman, Philip Quirke et al. · Journal of Clinical Oncology · 2008 · 275 citations · Full text

Intermittent versus continuous oxaliplatin and fluoropyrimidine combination chemotherapy for first-line treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial

Richard Adams, Angela Meade, Richard H. Wilson et al. · The Lancet Oncology · 2011 · 262 citations · Full text